SII is the first indigenous company that has sought emergency approval for the vaccine developed along with global pharma giant AstraZeneca and Oxford University.
Recouping the dent caused by the Hindenburg Research report, Gautam Adani's networth shot up 95 per cent to Rs 11.6 lakh crore last year, which helped him replace Mukesh Ambani to become the richest Indian, a report said on Thursday. Reliance Industries chairman and managing director Ambani's overall networth increased by 25 per cent to Rs 10.14 lakh crore, as per the 2024 Hurun India Rich List. In 2023's report, Adani's wealth declined by 57 per cent to Rs 4.74 lakh crore, and Ambani was way ahead with a fortune of Rs 8.08 lakh crore.
Covovax is likely to be available on the portal in a few days at a price of Rs 225 per dose plus applicable GST.
The DCGI also directed Serum Institute of India to increase the safety monitoring of the subjects already vaccinated as part of the trial, and submit the plan and report.
Vaccine manufacturer Serum Institute of India on Friday said Rabivax, the country's first Human Diploid Cell rabies vaccine launched by the company recently, would trigger the company's market share in this segment to about 30 per cent from the curre
'The US has invoked the Defence Act and banned export of raw materials.' 'This is as good as banning vaccines.'
The Bombay high court on Monday said content posted by two individuals and their organisations against vaccine manufacturing major Serum Institute of India (SII) was "prima facie defamatory" and directed them to delete it.
'We seem to be in a situation where we can do little, and nothing needs to be done anyway.'
Pharma giant AstraZeneca's Covid-19 vaccine is being withdrawn worldwide after the company acknowledged for the first time in court documents that it can cause a rare and dangerous side effect, according to a report in the British newspaper The Telegraph.
50 lakh doses of 'Covishield' vaccine earmarked by the Serum Institute for export to the United Kingdom have now been made available for the inoculation of 18-44 age group in 21 states/UTs in India, amid a surge in COVID-19 cases, official sources said.
Serum Institute has the capacity to make 250 million doses of Covishield monthly.
SII's CEO Adar Poonawalla took to Twitter to announce the "philanthropic" gesture.
Maharashtra Chief Minister Uddhav Thackeray on Friday said that whether the fire at the Serum Institute of India (SII) was an accident or sabotage will be known only after the probe gets over.
Currently, Covishield and other COVID vaccines are approved for people above the age of 18 years.
Adar Poonawalla says it took a five-minute chat with his father Cyrus before making the decision to manufacture Covishield. The bet paid off, and handsomely. Serum Institute now has the capacity to make 4 billion doses of Covishield annually.
What the UK is getting out of the Serum Institute is what India is losing. And the responsibility of the Indian State ought to have been to dictate where Serum Institute's vaccine doses should go, argues Ambassador M K Bhadrakumar.
An FIR was launched against some unidentified persons for cheating the SII for more than Rs 1 crore, said the officials on Sunday.
We should be relieved that we got the doses but we must also know where they came from and who was and who was not responsible for this achievement, notes Aakar Patel.
The Centre on Wednesday placed a second purchase order with the Serum Institute of India for the supply of one crore doses of Oxford-AstraZeneca COVID-19 vaccine 'Covishield', each costing Rs 210, including GST, sources said.
It has been approved by the European Medicines Agency for conditional marketing authorisation.
Siddharth Roy Kapur's RKF aims to raise around $50 million by offering up to a 50 per cent stake in the company.
Tope also informed that the Centre has asked the state to reduce the number of inoculation centers from 511 to 350, saying the government should focus on other emergencies also.
Dominic Xavier salutes every single person involved in making this miracle possible.
Covaxin is being indigenously developed by Bharat Biotech in collaboration with the Indian Council of Medical Research (ICMR).
Serum Institute along with other vaccine producers have agreed with the government to sacrifice profits. There is no vaccine industry on the planet that has agreed to provide vaccines at such a subsidised price, he added.
The Adani family, led by Chairman Gautam Adani, is the most valued first-generation family business at Rs 15.44 trillion.
We have applied for marketing authorisation to the EMA through AstraZeneca. We will not sell the vaccine in the EU, said a company source.
Given the recurring outbreaks in the last five years, the government is considering domestic manufacturing of monoclonal antibodies for treating Nipah virus infections and is in talks with Serum Institute of India, report Shine Jacob and Sohini Das.
'Even if Serum Institute and Bharat Biotech were successful in ramping up production overnight, what happens to the capacity after the demand from India is met?' asks Sanjeev Nayyar.
Apart from making efforts to meet the requirements of India, the company is also trying its best to balance the needs of the rest of the world, he added.
Serum Institute of India, the world's largest vaccine manufacturer, has a licence to produce the shot and has already manufactured close to 50 million doses.
Pune-based entrepreneur's unlisted company is already the largest vaccine manufacturer in the world and the networth has been helped by vaccine distribution and manufacturing potential of his business, it added. Recentrly, Serum struck an agreement with AstraZeneca to manufacture 1 billion doses of coronavirus vaccine being developed by Oxford University.
The fact sheet also asked people to inform the vaccinator or a supervising official about their medical condition before taking the vaccine.
India currently does not have any XBB 1.5 variant-based vaccines available.
The development comes after Prakash Kumar Singh, the Director, Government and Regulatory Affairs at SII, informed the Union health ministry that the firm would be able to supply 20.29 crore doses of Covishied in the month of September.
United Kingdom-headquartered pharmaceutical giant AstraZeneca (AZ) has admitted that in 'very rare cases' its Covid vaccine can cause a blood clot related side effect but the causal link is unknown, according to court papers being quoted in the UK media.
Serum Institute of India (SII) and Bharat Biotech have also stopped producing the Covishield and Covaxin vaccines respectively.
The Union Health Ministry on Friday announced that those above the age of 18 years who have completed nine months after the administration of the second dose will be eligible for the precaution dose.
Several states and UTs including Delhi, Maharashtra, Karnataka and Telangana have decided to opt for global tenders for procurement of anti-coronavirus shots with the domestic supply falling short to meet the rising demand.
The approval by the Drugs Controller General of India (DCGI) was given on the basis of recommendations submitted by a COVID-19 subject expert committee (SEC) of the Central Drugs Standard Control Organisation (CDSCO).
© 2026 Rediff.com - Advertise with us - Disclaimer - Privacy Policy - Sitemap - Feedback - About us - Terms of use - Grievances